1871-P: Retrospective Analysis and Comparison of Dexcom and Libre Continuous Glucose Monitoring Systems in Automated Insulin Delivery Users: The Delica_01 Study
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1871-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SILVIA BASTA und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: CGM systems are essential in managing type 1 diabetes (T1D), especially when used alongside automated insulin delivery. However, real-world data comparing different CGM systems, integrated in AID therapy, remain limited. This retrospective study compared glycemic outcomes, specifically time in range, between users of Dexcom G6/G7 and FreeStyle Libre 2/3 CGM systems combined with the CamAPS FX-YpsoPump AID system.
Methods
Adult individuals with T1D using Dexcom G6/G7 or FreeStyle Libre 2/3 CGMs with the CamAPS FX system were included. Data of AID users was taken in if they had continuous ≥14 days of valid CGM data. The primary outcome was time in range (70-180 mg/dL), secondary outcomes were TBR and TAR.
Results
Data from 52 individuals were analyzed (Dexcom: n=36; Libre: n=16). During a mean use of 89 ± 0.2 days, median HbA1c was 49.4 ± 9.0 mmol/mol for Dexcom users and 52.4 ± 7.6 mmol/mol for Libre users. Table 1 compares the TIR, TBR, and TAR between Dexcom and Libre users.
Conclusion
Dexcom G6/G7 (n=35/1) use within CamAPS FX AID therapy was associated with numerically higher TIR compared with FreeStyle Libre 2/3 (n=1/15). These findings should be interpreted with caution given the small sample size, short observation period and lack of statistical power. Larger prospective studies are needed to confirm potential differences between CGM systems in AID therapy. Disclosure S. Basta: None. P.M. Baumann: None. M. Cigler: None. F. Aberer: Advisory Panel; Ended; Bayer AG, Eli Lilly and Company. D.A. Hochfellner: Speaker's Bureau; Ended; Sanofi. Stock/Shareholder; Ended; Novo Nordisk A/S. D.A. Kraus: None. J.K. Mader: Research Support; Current; A. Menarini Diagnostics. Advisory Panel; Current; Abbott Diabetes. Speaker's Bureau; Current; Abbott Diabetes. Advisory Panel; Current; Becton, Dickinson and Company. Speaker's Bureau; Current; Becton, Dickinson and Company. Advisory Panel; Current; Insulet Corporation, Eli Lilly and Company. Speaker's Bureau; Current; Eli Lilly and Company. Advisory Panel; Current; Sanofi. Speaker's Bureau; Current; Sanofi. Advisory Panel; Current; Novo Nordisk A/S. Speaker's Bureau; Current; Novo Nordisk A/S. Advisory Panel; Current; Roche Diagnostics. Speaker's Bureau; Current; Roche Diagnostics. Advisory Panel; Current; Medtronic, Tandem Diabetes Care, Inc., Omnipod. Stock/Shareholder; Current; decide Clinical Software GmbH. Advisory Panel; Current; Dexcom, Inc. Speaker's Bureau; Current; Dexcom, Inc., Sinocare, Buzud. Advisory Panel; Current; Biomea Fusion, Pharmasens. Stock/Shareholder; Current; elyte Diagnostics. Other - CMO (unpaid); Current; elyte Diagnostics. Speaker's Bureau; Current; A. Menarini Diagnostics. Board Member; Current; OMNIA by AI APS. Advisory Panel; Current; Triple Jump.
Zitieren
APA
BASTA, S., BAUMANN, P. M., CIGLER, M., ABERER, F., HOCHFELLNER, D. A., KRAUS, D. A., & MADER, J. K. (2026). 1871-P: Retrospective Analysis and Comparison of Dexcom and Libre Continuous Glucose Monitoring Systems in Automated Insulin Delivery Users: The Delica_01 Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1871-p
Vancouver
BASTA S, BAUMANN PM, CIGLER M, ABERER F, HOCHFELLNER DA, KRAUS DA, et al. 1871-P: Retrospective Analysis and Comparison of Dexcom and Libre Continuous Glucose Monitoring Systems in Automated Insulin Delivery Users: The Delica_01 Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1871-p
BibTeX
@article{BASTA2026,
author = {BASTA, SILVIA and BAUMANN, PETRA M. and CIGLER, MONIKA and ABERER, FELIX and HOCHFELLNER, DANIEL A. and KRAUS, DANIEL A. and MADER, JULIA K.},
title = {1871-P: Retrospective Analysis and Comparison of Dexcom and Libre Continuous Glucose Monitoring Systems in Automated Insulin Delivery Users: The Delica_01 Study},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1871-p}
}
EUVIMED